Cellectar Biosciences saw a 27.9% increase in short interest in July, reaching a 4.5-day days-to-cover ratio.
Cellectar Biosciences (CLRB) saw a 27.9% increase in short interest in July, reaching 2.84 million shares and a 4.5-day days-to-cover ratio. Shares were flat at $2.03. The company reported a better-than-expected Qtr EPS of ($0.40) vs. analysts' consensus of ($0.50). CLRB focuses on cancer treatment drugs, with lead candidate CLR 131 in clinical trials for B-cell malignancies and other cancers.
August 18, 2024
3 Articles